Cargando…

Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients

Background and Objectives: We aim to compare the diagnostic performance of Protein induced by vitamin K absence-II (PIVKA-II), a biomarker for hepatocellular carcinoma (HCC), and alpha-fetoprotein (AFP) in differentiating HCC and non-malignant high-risk (NMHR) groups and to determine their cut-off v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hadi, Hana, Wan Shuaib, Wan Muhammad Azfar, Raja Ali, Raja Affendi, Othman, Hanita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416286/ https://www.ncbi.nlm.nih.gov/pubmed/36013482 http://dx.doi.org/10.3390/medicina58081015

Ejemplares similares

Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma
por: Park, Sang Joon, et al.
Publicado: (2017)

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
por: Kim, Do Young, et al.
Publicado: (2023)

The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
por: Qi, Famei, et al.
Publicado: (2019)

Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients
por: Ren, Tianying, et al.
Publicado: (2023)

Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma
por: Park, Hana, et al.
Publicado: (2013)

Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis
por: Liu, Siyu, et al.
Publicado: (2022)

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
por: Feng, Honglei, et al.
Publicado: (2021)

The value of PIVKA-Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma
por: Lee, Qiuyan, et al.
Publicado: (2021)

Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis
por: Chan, Henry L Y, et al.
Publicado: (2022)

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma
por: Tian, Shan, et al.
Publicado: (2022)

Effect of PIVKA‐II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery
por: Cai, Yunshi, et al.
Publicado: (2023)

Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation
por: Si, Yuan-Quan, et al.
Publicado: (2020)

The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients
por: Xu, Fei, et al.
Publicado: (2021)

The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma
por: Tran, Vinh Thanh, et al.
Publicado: (2023)

PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients
por: Suttichaimongkol, Tanita, et al.
Publicado: (2023)

Impact of PIVKA-II in diagnosis of hepatocellular carcinoma
por: Zakhary, Nadia I., et al.
Publicado: (2013)

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
por: Sun, Xuqi, et al.
Publicado: (2021)

Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population
por: Zheng, Kepu, et al.
Publicado: (2023)

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma
por: Kaneko, Shun, et al.
Publicado: (2022)

Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm, Barcelona stage 0) - assessment with large number of cases
por: Tarao, Kazuo, et al.
Publicado: (2020)

Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers
por: An, Shu, et al.
Publicado: (2023)

Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma
por: Villalba-López, Francisco, et al.
Publicado: (2023)

Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data
por: Yu, Rentao, et al.
Publicado: (2017)

The Influence of Alcoholic Liver Disease on Serum PIVKA-II Levels in Patients without Hepatocellular Carcinoma
por: Kang, Keunhee, et al.
Publicado: (2015)

Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population
por: Yu, Rentao, et al.
Publicado: (2015)

PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma
por: Li, Tao, et al.
Publicado: (2019)

The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China
por: Ji, Jun, et al.
Publicado: (2021)

PIVKA-II as a surrogate marker for prognosis in patients with localized hepatocellular carcinoma receiving stereotactic body radiotherapy
por: Cho, Ick Joon, et al.
Publicado: (2022)

Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin
por: Qian, Xiang-Jun, et al.
Publicado: (2023)

Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients
por: Chen, Youran, et al.
Publicado: (2022)

SARS-CoV-2 S-RBD IgG & Neutralizing antibodies among different categories of health care workers post third dose BNT162b2 mRNA COVID-19 vaccine
por: Wan Shuaib, Wan Muhammad Azfar, et al.
Publicado: (2023)

Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients
por: Yu, Rentao, et al.
Publicado: (2016)

The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study
por: Sagar, Vandana M., et al.
Publicado: (2021)

Investigating a Prognostic Factor for Canine Hepatocellular Carcinoma: Analysis of Different Histological Grading Systems and the Role of PIVKA-II
por: Maniscalco, Lorella, et al.
Publicado: (2022)

Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma
por: Wang, Xiumei, et al.
Publicado: (2017)

Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma
por: HOU, SI-CONG, et al.
Publicado: (2013)

Corrigendum: Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients
por: Yu, Rentao, et al.
Publicado: (2016)

Solitary Muscle Metastasis of Hepatocellular Carcinoma to the Biceps Femoris Muscle with Only Elevated Serum PIVKA-II: A Case Report
por: Orita, Kazuki, et al.
Publicado: (2019)

Primary colon cancer with a high serum PIVKA-II level
por: Kato, Kazuya, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_p04vg56o5mnl0rkpqnm9cpufif